诺诚健华总监陆春华谈中国创新药发展原因

Group 1 - The core viewpoint is that the development of innovative drugs in China is supported by both capital market opportunities and policy reforms [1] - The Hong Kong Stock Exchange and the Sci-Tech Innovation Board have provided a platform for unprofitable companies to list, facilitating the growth of innovative pharmaceuticals over the past decade [1] - Policy support has significantly improved since the reform of the drug review system in 2015, accelerating the development of innovative drugs [1] Group 2 - The return of a large number of overseas Chinese professionals has contributed to the talent pool, further stimulating the growth of the industry [1]